Omega-3 polyunsaturated fatty acids for cardiovascular diseases: present, past and future

References

• Krumholz HM, Wang Y, Chen J, et al. Reduction in acute myocardial infarction mortality in the United States: risk-standardized mortality rates from 1995-2006. JAMA. 2009;302(7):767–773.
   PubMed Web of Science ®Google Scholar
• Kimura N, Keys A. Coronary heart disease in seven countries. X. Rural southern Japan. Circulation. 1970;41(4Suppl):I101–1112.
   PubMedGoogle Scholar
• Bang HO, Dyerberg J, Nielsen AB. Plasma lipid and lipoprotein pattern in Greenlandic West-coast Eskimos. Lancet. 1971;1(7710):1143–1145.
   PubMed Web of Science ®Google Scholar
• Bang HO, Dyerberg J, Hjoorne N. The composition of food consumed by Greenland Eskimos. Acta Med Scand. 1976;200(1–2):69–73.
   PubMedGoogle Scholar
• Sinclair HM. The diet of Canadian Indians and Eskimos. Br J Nutr. 1952;12:69–82.
   Google Scholar
• Parkinson AJ, Cruz AL, Heyward WL, et al. Elevated concentrations of plasma omega-3 polyunsaturated fatty acids among Alaskan Eskimos. Am J Clin Nutr. 1994;59(2):384–388.
   PubMed Web of Science ®Google Scholar
• GISSI-Prevenzione Investigators (Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto miocardicol). Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI-Prevenzione trial. Gruppo Italiano per lo Studio della Sopravvivenza nell’Infarto miocardico. Lancet. 1999;354(9177):447–455.
   PubMed Web of Science ®Google Scholar
• Tavazzi L, Maggioni AP, Marchioli R, et al. Effect of n-3 polyunsaturated fatty acids in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial. Lancet. 2008;372(9645):1223–1230.
   PubMed Web of Science ®Google Scholar
• Terano T, Hirai A, Hamazaki T, et al. Effect of oral administration of highly purified eicosapentaenoic acid on platelet function, blood viscosity and red cell deformability in healthy human subjects. Atherosclerosis. 1983;46(3):321–331.
   PubMed Web of Science ®Google Scholar
• Tatsuno I, Saito Y, Kudou K, et al. Efficacy and safety of TAK-085 compared with eicosapentaenoic acid in Japanese subjects with hypertriglyceridemia undergoing lifestyle modification: the omega-3 fatty acids randomized double-blind (ORD) study. J Clin Lipidol. 2013;7(3):199–207.
   PubMed Web of Science ®Google Scholar
• Tatsuno I, Saito Y, Kudou K, et al. Long-term safety and efficacy of TAK-085 in Japanese subjects with hypertriglyceridemia undergoing lifestyle modification: the omega-3 fatty acids randomized long-term (ORL) study. J Clin Lipidol. 2013;7(6):615–625.
   PubMed Web of Science ®Google Scholar
• Masson S, Latini R, Tacconi M, et al. Incorporation and washout of n-3 polyunsaturated fatty acids after diet supplementation in clinical studies. J Cardiovasc Med. 2007;8(Suppl 1):S4–S10.
   Google Scholar
• Nordoy A, Barstad L, Connor WE, et al. Absorption of the n-3 eicosapentaenoic and docosahexaenoic acids as ethyl esters and triglycerides by humans. Am J Clin Nutr. 1991;53(5):1185–1190.
   PubMed Web of Science ®Google Scholar
• Assmann G, Schulte H, Von Eckardstein A. Hypertriglyceridemia and elevated lipoprotein(a) are risk factors for major coronary events in middle-aged men. Am J Cardiol. 1996;77(14):1179–1184.
   PubMed Web of Science ®Google Scholar
• Nordestgaard BG, Varbo A. Triglycerides and cardiovascular disease. Lancet. 2014;384(9943):626–635.
   PubMed Web of Science ®Google Scholar
• McKenney JM, Sica D. Prescription omega-3 fatty acids for the treatment of hypertriglyceridemia. Am J Health Syst Pharm. 2007;64(6):595–605.
   PubMed Web of Science ®Google Scholar
• Harris WS, Bulchandani D. Why do omega-3 fatty acids lower serum triglycerides? Curr Opin Lipidol. 2006;17(4):387–393.
   PubMed Web of Science ®Google Scholar
• Bays HE, Tighe AP, Sadovsky R, et al. Prescription omega-3 fatty acids and their lipid effects: physiologic mechanisms of action and clinical implications. Expert Rev Cardiovasc Ther. 2008;6(3):391–409.
   PubMedGoogle Scholar
• Crosby J, Peloso GM, Auer PL, et al. Loss-of-function mutations in APOC3, triglycerides, and coronary disease. N Engl J Med. 2014;371(1):22–31.
   PubMed Web of Science ®Google Scholar
• Bays HE, Ballantyne CM, Kastelein JJ, et al. Eicosapentaenoic acid ethyl ester (AMR101) therapy in patients with very high triglyceride levels (from the Multi-center, plAcebo-controlled, Randomized, double-blINd, 12-week study with an open-label Extension [MARINE] trial). Am J Cardiol. 2011;108(5):682–690.
   PubMed Web of Science ®Google Scholar
• Ballantyne CM, Bays HE, Braeckman RA, et al. Icosapent ethyl (eicosapentaenoic acid ethyl ester): effects on apolipoprotein C-III in patients from the MARINE and ANCHOR studies. J Clin Lipidol. 2014;8(3):313–314.
   Google Scholar
• Tatsuno I, Kudou K, Kagawa T. Effect of TAK-085 on low-density lipoprotein particle size in patients with hypertriglyceridemia: a double-blind randomized clinical study. Cardiovasc Ther. 2015;33(6):317–323.
   PubMed Web of Science ®Google Scholar
• Geleijnse JM, Giltay EJ, Grobbee DE, et al. Blood pressure response to fish oil supplementation: metaregression analysis of randomized trials. J Hypertens. 2002;20(8):1493–1499.
   PubMed Web of Science ®Google Scholar
• Kris-Etherton PM, Harris WS, Appel LJ. Fish consumption, fish oil, omega-3 fatty acids, and cardiovascular disease. Circulation. 2002;106(21):2747–2757.
   PubMed Web of Science ®Google Scholar
• Robinson JG, Stone NJ. Antiatherosclerotic and antithrombotic effects of omega-3 fatty acids. Am J Cardiol. 2006;98(4A):39i–49i.
   PubMed Web of Science ®Google Scholar
• Wang Q, Liang X, Wang L, et al. Effect of omega-3 fatty acids supplementation on endothelial function: a meta-analysis of randomized controlled trials. Atherosclerosis. 2012;221(2):536–543.
   PubMed Web of Science ®Google Scholar
• Tousoulis D, Plastiras A, Siasos G, et al. Omega-3 PUFAs improved endothelial function and arterial stiffness with a parallel antiinflammatory effect in adults with metabolic syndrome. Atherosclerosis. 2014;232(1):10–16.
   PubMed Web of Science ®Google Scholar
• Merino J, Sala-Vila A, Kones R, et al. Increasing long-chain n-3PUFA consumption improves small peripheral artery function in patients at intermediate-high cardiovascular risk. J Nutr Biochemistry. 2014;25(6):642–646.
   PubMed Web of Science ®Google Scholar
• Chan DC, Pang J, Barrett PHR, et al. Effect of omega-3 fatty acid supplementation on arterial elasticity in patients with familial hypercholesterolaemia on statin therapy. Nutr Metab Cardiovasc Dis. 2016;26(12):6–11.
   Web of Science ®Google Scholar
• Tagetti A, Ericson U, Montagnana M, et al. Intakes of omega-3 polyunsaturated fatty acids and blood pressure change over time: possible interaction with genes involved in 20-HETE and EETs metabolism. Prostaglandins Other Lipid Mediat. 2015;120:126–133.
   PubMed Web of Science ®Google Scholar
• Mozaffarian D, Geelen A, Brouwer IA, et al. Effect of fish oil on heart rate in humans: a meta-analysis of randomized controlled trials. Circulation. 2005;112(13):1945–1952.
   PubMed Web of Science ®Google Scholar
• McLennan PL. Myocardial membrane fatty acids and the antiarrhythmic actions of dietary fish oil in animal models. Lipids. 2001;36(Suppl):S111–S114.
   PubMed Web of Science ®Google Scholar
• Leaf A, Kang JX, Xiao YF, et al. Clinical prevention of sudden cardiac death by n-3 polyunsaturated fatty acids and mechanism of prevention of arrhythmias by n-3 fish oils. Circulation. 2003;107(21):2646–2652.
   PubMed Web of Science ®Google Scholar
• Hisamatsu T, Miura K, Ohkubo T, et al. High long-chain n-3 fatty acid intake attenuates the effect of high resting heart rate on cardiovascular mortality risk: a 24-year follow-up of Japanese general population. J Cardiol. 2014;64(3):218–224.
   PubMed Web of Science ®Google Scholar
• Mozaffarian D, Rimm EB. Fish intake, contaminants, and human health: evaluating the risks and the benefits. JAMA. 2006;296(15):1885–1899.
   PubMed Web of Science ®Google Scholar
• Wang C, Harris WS, Chung M, et al. n-3 Fatty acids from fish or fish-oil supplements, but not alpha-linolenic acid, benefit cardiovascular disease outcomes in primary- and secondary-prevention studies: a systematic review. Am J Clin Nutr. 2006;84(1):5–17.
   PubMed Web of Science ®Google Scholar
• Kromann N, Green A. Epidemiological studies in the Upernavik district, Greenland. Incidence of some chronic diseases 1950-1974. Acta Med Scand. 1980;208(5):401–406.
   PubMedGoogle Scholar
• Prickett JD, Robinson DR, Steinberg AD. Dietary enrichment with the polyunsaturated fatty acid eicosapentaenoic acid prevents proteinuria and prolongs survival in NZB x NZW F1 mice. J Clin Invest. 1981;68(2):556–559.
   PubMed Web of Science ®Google Scholar
• Chang KJ, Saito H, Tatsuno I, et al. Role of 5-lipoxygenase products of arachidonic acid in cell-to-cell interaction between macrophages and natural killer cells in rat spleen. J Leukoc Biol. 1991;50(3):273–278.
   PubMed Web of Science ®Google Scholar
• Tatsuno I, Saito H, Chang KJ, et al. Comparison of the effect between leukotriene B4 and leukotriene B5 on the induction of interleukin 1-like activity and calcium mobilizing activity in human blood monocytes. Agents Actions. 1990;29(3–4):324–327.
   PubMedGoogle Scholar
• Cao RY, St Amand T, Grabner R, et al. Genetic and pharmacological inhibition of the 5-lipoxygenase/leukotriene pathway in atherosclerotic lesion development in ApoE deficient mice. Atherosclerosis. 2009;203(2):395–400.
   PubMed Web of Science ®Google Scholar
• Matsumoto M, Sata M, Fukuda D, et al. Orally administered eicosapentaenoic acid reduces and stabilizes atherosclerotic lesions in ApoE-deficient mice. Atherosclerosis. 2008;197(2):524–533.
   PubMed Web of Science ®Google Scholar
• Allaire J, Couture P, Leclerc M, et al. A randomized, crossover, head-to-head comparison of eicosapentaenoic acid and docosahexaenoic acid supplementation to reduce inflammation markers in men and women: the Comparing EPA to DHA (ComparED) Study. Am J Clin Nutr. 2016;104(2):280–287.
   PubMed Web of Science ®Google Scholar
• Halade GV, Rahman MM, Bhattacharya A, et al. Docosahexaenoic acid-enriched fish oil attenuates kidney disease and prolongs median and maximal life span of autoimmune lupus-prone mice. J Immunol. 2010;184(9):5280–5286.
   PubMed Web of Science ®Google Scholar
• Serhan CN, Hong S, Gronert K, et al. Resolvins: a family of bioactive products of omega-3 fatty acid transformation circuits initiated by aspirin treatment that counter proinflammation signals. J Exp Med. 2002;196(8):1025–1037.
   PubMed Web of Science ®Google Scholar
• Spite M, Norling LV, Summers L, et al. Resolvin D2 is a potent regulator of leukocytes and controls microbial sepsis. Nature. 2009;461(7268):1287–1291.
   PubMed Web of Science ®Google Scholar
• Merched AJ, Ko K, Gotlinger KH, et al. Atherosclerosis: evidence for impairment of resolution of vascular inflammation governed by specific lipid mediators. FASEB J. 2008;22(10):3595–3606.
   PubMed Web of Science ®Google Scholar
• Collins AJ, Li S, Ma JZ, et al. Cardiovascular disease in end-stage renal disease patients. Am J Kidney Dis. 2001;38(4 Suppl 1):S26–S29.
   PubMed Web of Science ®Google Scholar
• Lindner A, Charra B, Sherrard DJ, et al. Accelerated atherosclerosis in prolonged maintenance hemodialysis. N Engl J Med. 1974;290(13):697–701.
   PubMed Web of Science ®Google Scholar
• Kajbaf M, Khorvash F, Mortazavi M, et al. Does omega-3 supplementation decrease carotid intima-media thickening in hemodialysis patients? J Res Pharm Pract. 2016;5(4):252–252.
   PubMed Web of Science ®Google Scholar
• Rizos EC, Ntzani EE, Bika E, et al. Association between omega-3 fatty acid supplementation and risk of major cardiovascular disease events: a systematic review and meta-analysis. JAMA. 2012;308(10):1024–1033.
   PubMed Web of Science ®Google Scholar
• Miyagawa N, Miura K, Okuda N, et al. Long-chain n-3 polyunsaturated fatty acids intake and cardiovascular disease mortality risk in Japanese: a 24-year follow-up of NIPPON DATA80. Atherosclerosis. 2014;232(2):384–389.
   PubMed Web of Science ®Google Scholar
• De Oliveira Otto MC, Wu JHY, Baylin A, et al. Circulating and dietary omega-3 and omega-6 polyunsaturated fatty acids and incidence of CVD in the multi-ethnic study of atherosclerosis. J Am Heart Assoc. 2013;2(6):e000506–e000506.
   PubMed Web of Science ®Google Scholar
• Galan P, Kesse-Guyot E, Czernichow S, et al. Effects of B vitamins and omega 3 fatty acids on cardiovascular diseases: a randomised placebo controlled trial. Bmj. 2010;341:c6273.
   PubMed Web of Science ®Google Scholar
• Kromhout D, Giltay EJ, Geleijnse JM. n-3 fatty acids and cardiovascular events after myocardial infarction. N Engl J Med. 2010;363(21):2015–2026.
   PubMed Web of Science ®Google Scholar
• Roncaglioni MC, Tombesi M, Avanzini F, et al. n-3 fatty acids in patients with multiple cardiovascular risk factors. N Engl J Med. 2013;368(19):1800–1808.
   PubMed Web of Science ®Google Scholar
• Rhee JJ, Kim E, Buring JE, et al. Fish consumption, omega-3 fatty acids, and risk of cardiovascular disease. Am J Prev Med. 2016;52(1):10–19.
   PubMed Web of Science ®Google Scholar
• Gobbo LCD, Imamura F, Aslibekyan S, et al. ω-3 polyunsaturated fatty acid biomarkers and coronary heart disease pooling project of 19 cohort studies. JAMA Intern Med. 2016;94305:1–12.
   Google Scholar
• Mozaffarian D, Lemaitre RN, Kuller LH, et al. Cardiac benefits of fish consumption may depend on the type of fish meal consumed: the Cardiovascular Health Study. Circulation. 2003;107(10):1372–1377.
   PubMed Web of Science ®Google Scholar
• Iso H, Kobayashi M, Ishihara J, et al. Intake of fish and n3 fatty acids and risk of coronary heart disease among Japanese: the Japan Public Health Center-Based (JPHC) Study Cohort I. Circulation. 2006;113(2):195–202.
   PubMed Web of Science ®Google Scholar
• Alexander DD, Miller PE, Van Elswyk ME, et al. A meta-analysis of randomized controlled trials and prospective cohort studies of eicosapentaenoic and docosahexaenoic long-chain omega-3 fatty acids and coronary heart disease risk. Mayo Clin Proc. 2017;92(1):15–29.
   PubMed Web of Science ®Google Scholar
• O’Keefe JH, Jacob D, Lavie CJ. Omega-3 fatty acid therapy: the tide turns for a fish story. Mayo Clin Proc. 2017;92(1):1–3.
   PubMed Web of Science ®Google Scholar
• Marchioli R, Barzi F, Bomba E, et al. Early protection against sudden death by n-3 polyunsaturated fatty acids after myocardial infarction: time-course analysis of the results of the Gruppo Italiano per lo Studio della Sopravvivenza nell’Infarto Miocardico (GISSI)-Prevenzione. Circulation. 2002;105(16):1897–1903.
   PubMed Web of Science ®Google Scholar
• Yokoyama M, Origasa H, Matsuzaki M, et al. Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): a randomised open-label, blinded endpoint analysis. Lancet. 2007;369(9567):1090–1098.
   PubMed Web of Science ®Google Scholar
• Siscovick DS, Barringer TA, Fretts AM, et al. Omega-3 polyunsaturated fatty acid (fish oil) supplementation and the prevention of clinical cardiovascular disease: a science advisory from the American Heart Association. Circulation. 2017;135(15):e867–e884.
   PubMed Web of Science ®Google Scholar
• Bosch J, Gerstein HC, Dagenais GR, et al. n-3 fatty acids and cardiovascular outcomes in patients with dysglycemia. N Engl J Med. 2012;367(4):309–318.
   PubMed Web of Science ®Google Scholar
• Marangoni F, Novo G, Perna G, et al. Omega-6 and omega-3 polyunsaturated fatty acid levels are reduced in whole blood of Italian patients with a recent myocardial infarction: the AGE-IM study. Atherosclerosis. 2014;232(2):334–338.
   PubMed Web of Science ®Google Scholar
• Koh AS, Pan A, Wang R, et al. The association between dietary omega-3 fatty acids and cardiovascular death: the Singapore Chinese Health Study. Eur J Prev Cardiol. 2015;22(3):364–372.
   PubMed Web of Science ®Google Scholar
• Itakura H, Yokoyama M, Matsuzaki M, et al. Relationships between plasma fatty acid composition and coronary artery disease. J Atheroscler Thromb. 2011;18(2):99–107.
   PubMed Web of Science ®Google Scholar
• Hillege HL, Fidler V, Diercks GFH, et al. Urinary albumin excretion predicts cardiovascular and noncardiovascular mortality in general population. Circulation. 2002;106(14):1777–1782.
   PubMed Web of Science ®Google Scholar
• Yuyun MF, Khaw K-T, Luben R, et al. Microalbuminuria independently predicts all-cause and cardiovascular mortality in a British population: the European Prospective Investigation into Cancer in Norfolk (EPIC-Norfolk) population study. Int J Epidemiol. 2004;33(1):189–198.
   PubMed Web of Science ®Google Scholar
• Fukami A, Adachi H, Hirai Y, et al. Association of serum eicosapentaenoic acid to arachidonic acid ratio with microalbuminuria in a population of community-dwelling Japanese. Atherosclerosis. 2015;239(2):577–582.
   PubMed Web of Science ®Google Scholar
• Malik AR, Sultan S, Turner ST, et al. Urinary albumin excretion is associated with impaired flow- and nitroglycerin-mediated brachial artery dilatation in hypertensive adults. J Hum Hypertens. 2007;21(3):231–238.
   PubMed Web of Science ®Google Scholar
• Hermans MM, Henry R, Dekker JM, et al. Estimated glomerular filtration rate and urinary albumin excretion are independently associated with greater arterial stiffness: the Hoorn Study. J Am Soc Nephrol. 2007;18(6):1942–1952.
   PubMed Web of Science ®Google Scholar
• Stehouwer CD, Smulders YM. Microalbuminuria and risk for cardiovascular disease: analysis of potential mechanisms. J Am Soc Nephrol. 2006;17(8):2106–2111.
   PubMed Web of Science ®Google Scholar
• Rizzo AM, Montorfano G, Negroni M, et al. A rapid method for determining arachidonic: eicosapentaenoicacid ratios in whole blood lipids: correlation with erythrocyte membrane ratios and validation in a large Italian population of various ages and pathologies. Lipids Health Dis. 2010;9:7.
   PubMed Web of Science ®Google Scholar
• Mozaffarian D, Bryson CL, Lemaitre RN, et al. Fish intake and risk of incident heart failure. J Am Coll Cardiol. 2005;45(12):2015–2021.
   PubMed Web of Science ®Google Scholar
• Belin RJ, Greenland P, Martin L, et al. Fish intake and the risk of incident heart failure: the Women’s Health Initiative. Circ Heart Fail. 2011;4(4):404–413.
   PubMed Web of Science ®Google Scholar
• Ghio S, Scelsi L, Latini R, et al. Effects of n-3 polyunsaturated fatty acids and of rosuvastatin on left ventricular function in chronic heart failure: a substudy of GISSI-HF trial. Eur J Heart Fail. 2010;12(12):1345–1353.
   PubMed Web of Science ®Google Scholar
• Yancy CW, Jessup M, Bozkurt B, et al. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Circulation. 2013;128(16):e240–e319.
   PubMed Web of Science ®Google Scholar
• Leaf A, Albert CM, Josephson M, et al. Prevention of fatal arrhythmias in high-risk subjects by fish oil n-3 fatty acid intake. Circulation. 2005;112(18):2762–2768.
   PubMed Web of Science ®Google Scholar
• Brouwer IA, Zock PL, Camm AJ, et al. Effect of fish oil on ventricular tachyarrhythmia and death in patients with implantable cardioverter defibrillators: the Study on omega-3 Fatty Acids and Ventricular Arrhythmia (SOFA) randomized trial. JAMA. 2006;295(22):2613–2619.
   PubMed Web of Science ®Google Scholar
• Brouwer IA, Raitt MH, Dullemeijer C, et al. Effect of fish oil on ventricular tachyarrhythmia in three studies in patients with implantable cardioverter defibrillators. Eur Heart J. 2009;30(7):820–826.
   PubMed Web of Science ®Google Scholar
• Mozaffarian D, Psaty BM, Rimm EB, et al. Fish intake and risk of incident atrial fibrillation. Circulation. 2004;110(4):368–373.
   PubMed Web of Science ®Google Scholar
• Mozaffarian D, Wu JH, De Oliveira Otto MC, et al. Fish oil and post-operative atrial fibrillation: a meta-analysis of randomized controlled trials. J Am Coll Cardiol. 2013;61(21):2194–2196.
   PubMed Web of Science ®Google Scholar
• Mariani J, Doval HC, Nul D, et al. N-3 polyunsaturated fatty acids to prevent atrial fibrillation: updated systematic review and meta-analysis of randomized controlled trials. J Am Heart Assoc. 2013;2(1):e005033.
   PubMed Web of Science ®Google Scholar
• He K, Song Y, Daviglus ML, et al. Fish consumption and incidence of stroke: a meta-analysis of cohort studies. Stroke. 2004;35(7):1538–1542.
   PubMed Web of Science ®Google Scholar
• Xun P, Qin B, Song Y, et al. Fish consumption and risk of stroke and its subtypes: accumulative evidence from a meta-analysis of prospective cohort studies. Eur J Clin Nutr. 2012;66(11):1199–1207.
   PubMed Web of Science ®Google Scholar
• Tanaka K, Ishikawa Y, Yokoyama M, et al. Reduction in the recurrence of stroke by eicosapentaenoic acid for hypercholesterolemic patients: subanalysis of the JELIS trial. Stroke. 2008;39(7):2052–2058.
   PubMed Web of Science ®Google Scholar
• Heydari B, Abdullah S, Pottala JV, et al. Effect of omega-3 acid ethyl esters on left ventricular remodeling after acute myocardial infarction: the OMEGA-REMODEL randomized clinical trial. Circulation. 2016;134(5):378–391.
   PubMed Web of Science ®Google Scholar
• Serhan CN. Pro-resolving lipid mediators are leads for resolution physiology. Nature. 2014;510(7503):92–101.
   PubMed Web of Science ®Google Scholar
• Keyes KT, Ye Y, Lin Y, et al. Resolvin E1 protects the rat heart against reperfusion injury. Am J Physiol Heart Circ Physiol. 2010;299(1):H153–H164.
   PubMed Web of Science ®Google Scholar
• Kain V, Ingle KA, Colas RA, et al. Resolvin D1 activates the inflammation resolving response at splenic and ventricular site following myocardial infarction leading to improved ventricular function. J Mol Cell Cardiol. 2015;84:24–35.
   PubMed Web of Science ®Google Scholar
• Endo J, Sano M, Isobe Y, et al. 18-HEPE, an n-3 fatty acid metabolite released by macrophages, prevents pressure overload-induced maladaptive cardiac remodeling. J Exp Med. 2014;211(8):1673–1688.
   PubMed Web of Science ®Google Scholar
• Tatsuno I. Is the effect of omega-3 polyunsaturated fatty acids dependent on life-style, severity of disease, and use of concomitant medications? J Atheroscler Thromb. 2017;24(3):256–257.
   PubMed Web of Science ®Google Scholar
• Ninomiya T, Nagata M, Hata J, et al. Association between ratio of serum eicosapentaenoic acid to arachidonic acid and risk of cardiovascular disease: the Hisayama Study. Atherosclerosis. 2013;231(2):261–267.
   PubMed Web of Science ®Google Scholar
• Fulcher J, O’Connell R, Voysey M, et al. Efficacy and safety of LDL-lowering therapy among men and women: meta-analysis of individual data from 174 000 participants in 27 randomised trials. Lancet. 2015;385(9976):1397–1405.
   PubMed Web of Science ®Google Scholar
• Sampson UK, Fazio S, Linton MRF. Residual cardiovascular risk despite optimal LDL cholesterol reduction with statins: the evidence, etiology, and therapeutic challenges. Curr Atheroscler Rep. 2012;14(1):1–10.
   PubMed Web of Science ®Google Scholar
• Nozue T, Yamamoto S, Tohyama S, et al. Comparison of effects of serum n-3 to n-6 polyunsaturated fatty acids ratios on coronary atherosclerosis in statin-treated patients with coronary artery disease. Am J Cardiol. 2013;111(1):6–11.
   PubMed Web of Science ®Google Scholar
• Abedi E, Sahari MA. Long-chain polyunsaturated fatty acid sources and evaluation of their nutritional and functional properties. Food Sci Nutr. 2014;2(5):443–463.
   PubMedGoogle Scholar